OncoGenex Grabs $60 Million Upfront From Teva for Rights to Cancer Drug

Bothell, WA-based OncoGenex Pharmaceuticals announced Monday it has clinched $60 million in upfront payments from Israel-based Teva Pharmaceutical for the right to co-develop an experimental prostate cancer drug that has been shown to prolong patients’ lives in a small study.
Xconomy